Spectral Medical Inc T.EDT

Alternate Symbol(s): EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.

TSX:EDT - Post by User

Spectral Medical Inc > Data

<< Previous

Bullboard Posts

Next >>

Comment by hmmmmmmmmon Feb 22, 2024 12:47pm

116 Views

Post# 35893609

RE:RE:Data

As per pg 14 and 18 of the Anual Meeting Presentation:

"At 90 patients Baxter will have access to raw data (no statistical analysis)… potential opportunity to release crude data to broader audience"

"Spectral Catalysts

• Tigris interim patient enrollment - 90 patients / Baxter milestone payment #2

• Release of crude mortality data at 90 patients"

https://spectraldx.com/wp-content/uploads/2023/06/Spectral-agm-2023-presentation.pdf

<< Previous

Bullboard Posts

Next >>

Sirios Resource discovers visible gold in Quebec